Lifitegrast Drug Asset Due Diligence Report 2026

This Lifitegrast Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Lifitegrast can convert its Small molecule drug profile and CD11a biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Lifitegrast (query alias: lifitegrast)
Modality / target	Small molecule drug; CD11a; CD11a antagonists
Highest global status	Approved
Originator	Shire Development LLC
Active developers	Novartis AG, Bausch & Lomb, Inc., Novartis Pharmaceuticals Corp.

The MCP disease footprint includes Dry Eye Syndromes. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07490535	Phase 4	Not yet recruiting	36	Change in proteomic expression of tear fluid biomarkers
NCT07560735	Phase 4	Not yet recruiting	30	Change in immune cell density in subjects with dry eye disease treated with lifitegrast
ChiCTR2500113402	Phase 3	Completed	311	Mean change from baseline in inferior corneal fluorescein staining score (ICSS) in the experimental group and the placebo group

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers

Phase 4; n=45; evaluation: not stated. Reported fields: -; -; Baseline(Median) = 71 score on a scale (Full Range, 8 - 93)

An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects With Dry Eye Disease in a Dry Eye Chamber

Phase 2; n=56; evaluation: not stated. Reported fields: Change From Baseline in Ocular Discomfort(Least Squares Mean) = 1.35 score on a scale (Standard Error, 0.21); Change From Baseline in Ocular Discomfort(Least Squares Mean) = 2.07 score on a scale (Standard Error, 0.25); -

Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

Phase 4; n=32; evaluation: not stated. Reported fields: Efficacy of Lifitegrast Ophthalmic Solution 5% in Treating the Symptoms of Dry Eye in Contact Lens Wearers as Measured by Change in Total CLDEQ-8 Score From Baseline to Week 8(Median) = -4 units on a scale (Inter-Quartile Range, -8 to -2); Efficacy of Lifitegrast Ophthalmic Solution 5% in Treating the Symptoms of Dry Eye in Contact Lens Wearers as Measured by Change in Total CLDEQ-8 Score From Baseline to Week 8(Median): P-Value = 0.69; Efficacy of Lifitegrast Ophthalmic Solution 5% in Treating the Symptoms of Dry Eye in Contact Lens Wearers as Measured by Change in Total CLDEQ-8 Score From Baseline to Week 8(Median) = -5 units on a scale (Inter-Quartile Range, -8 to -2)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Lifitegrast addresses Dry Eye Syndromes. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-06-30	Novartis completes divestment of ‘front of eye’ ophthalmology assets	Phase 2	US$1,750.0M upfront; US$750.0M milestones; US$2,500.0M stated total
	Novartis purchases global rights to Takeda's Xiidra for the treatment of dry eye disease.	Approved	US$5,300.0M stated total
2009-05-09	Sunesis Pharmaceuticals Announces the Sale of its LFA-1 Inhibitor Program to SARcode Corporation	Phase 1	US$2.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Use of lifitegrast in preparation of drug for treating retinal artery occlusion injury”. The milestone feed surfaced a patent-application signal described as “Method of preparing lifitegrast via transesterification and the compound thereof”. The milestone feed surfaced a patent-application signal described as “Novel salts of lifitegrast and its crystalline forms”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO